<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30418174</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1558-8238</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>The Journal of clinical investigation</Title>                <ISOAbbreviation>J. Clin. Invest.</ISOAbbreviation>            </Journal>            <ArticleTitle>Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI121679</ELocationID>            <ELocationID EIdType="pii" ValidYN="Y">121679</ELocationID>            <Abstract>                <AbstractText>The agonistic/antagonistic biocharacter of selective estrogen receptor modulators (SERMs) can have therapeutic advantages, particularly in the case of premenopausal breast cancers. Although the contradictory effects of these modulators have been studied in terms of crosstalk between the estrogen receptor Î± (ER) and coactivator dynamics and growth factor signaling, the molecular basis of these mechanisms is still obscure. We identify a series of regulatory mechanisms controlling cofactor dynamics on ER and SERM function, whose activities require F-box protein 22 (Fbxo22). Skp1, Cullin1, F-box-containing complex (SCFFbxo22) ubiquitylated lysine demethylase 4B (KDM4B) complexed with tamoxifen-bound (TAM-bound) ER, whose degradation released steroid receptor coactivator (SRC) from ER. Depletion of Fbxo22 resulted in ER-dependent transcriptional activation via transactivation function 1 (AF1) function, even in the presence of SERMs. In living cells, TAM released SRC and KDM4B from ER in a Fbxo22-dependent manner. SRC release by TAM required Fbxo22 on almost all ER-SRC-bound enhancers and promoters. TAM failed to prevent the growth of Fbxo22-depleted, ER-positive breast cancers both in vitro and in vivo. Clinically, a low level of Fbxo22 in tumor tissues predicted a poorer outcome in ER-positive/human epidermal growth factor receptor type 2-negative (HER2-negative) breast cancers with high hazard ratios, independently of other markers such as Ki-67 and node status. We propose that the level of Fbxo22 in tumor tissues defines a new subclass of ER-positive breast cancers for which SCFFbxo22-mediated KDM4B degradation in patients can be a therapeutic target for the next generation of SERMs.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Johmura</LastName>                    <ForeName>Yoshikazu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maeda</LastName>                    <ForeName>Ichiro</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suzuki</LastName>                    <ForeName>Narumi</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Wenwen</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goda</LastName>                    <ForeName>Atsushi</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morita</LastName>                    <ForeName>Mariko</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Genome Research, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yamaguchi</LastName>                    <ForeName>Kiyoshi</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Genome Research, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yamamoto</LastName>                    <ForeName>Mizuki</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cellular and Molecular Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nagasawa</LastName>                    <ForeName>Satoi</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kojima</LastName>                    <ForeName>Yasuyuki</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tsugawa</LastName>                    <ForeName>Koichiro</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Inoue</LastName>                    <ForeName>Natsuko</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miyoshi</LastName>                    <ForeName>Yasuo</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Osako</LastName>                    <ForeName>Tomo</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, The Cancer Institute Hospital, and.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akiyama</LastName>                    <ForeName>Futoshi</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, The Cancer Institute Hospital, and.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maruyama</LastName>                    <ForeName>Reo</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Project for Cancer Epigenomics, the Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Inoue</LastName>                    <ForeName>Jun-Ichiro</ForeName>                    <Initials>JI</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cellular and Molecular Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Furukawa</LastName>                    <ForeName>Yoichi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Genome Research, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ohta</LastName>                    <ForeName>Tomohiko</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nakanishi</LastName>                    <ForeName>Makoto</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Clin Invest</MedlineTA>            <NlmUniqueID>7802877</NlmUniqueID>            <ISSNLinking>0021-9738</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Endocrinology</Keyword>            <Keyword MajorTopicYN="N">Molecular diagnosis</Keyword>            <Keyword MajorTopicYN="N">Ubiquitin-proteosome system</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30418174</ArticleId>            <ArticleId IdType="pii">121679</ArticleId>            <ArticleId IdType="doi">10.1172/JCI121679</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>